de Melo Maria Eduarda Cardoso, da Silva Letícia Marques Gomes, Cavalcante Ana Carolina Costa, Lima Josivan Gomes, Campos Julliane Tamara Araújo de Melo
Laboratório de Biologia Molecular e Genômica, Departamento de Biologia Celular e Genética, Centro de Biociências, Universidade Federal do Rio Grande do Norte (UFRN), Natal 59072-900, RN, Brazil.
Laboratório de Genética Molecular e Metabolismo, Instituto de Medicina Tropical do Rio Grande do Norte, Centro de Biociências, Universidade Federal do Rio Grande do Norte (UFRN), Natal 59072-900, RN, Brazil.
Int J Mol Sci. 2025 Jun 5;26(11):5416. doi: 10.3390/ijms26115416.
1-Acylglycerol-3-phosphate O-acyltransferase (1-AGPAT) is an enzyme family composed of 11 isoforms. Notably, 1-AGPAT 2, the most studied isoform since its discovery, is a critical enzyme in the triglyceride synthesis pathway, converting lysophosphatidic acid to phosphatidic acid. In addition, gene expression is shown to be essential for adipocyte development and maturation. Defects in are responsible for significant pathophysiological alterations related to adipose tissue (AT). Pathogenic variants in this gene are the molecular etiology of Congenital Generalized Lipodystrophy type 1 (CGL1), in which fatty tissue is absent from birth. Metabolically, these individuals have several metabolic complications, including hypoleptinemia, hypoadiponectinemia, hyperglycemia, and hypertriglyceridemia. Furthermore, numerous pathogenic variants that enormously affect the amino acid sequence, the tertiary structure of 1-AGPAT 2, and their transmembrane and functional domains were found in CGL1 patients. However, studies investigating the genotype-phenotype relationship in this disease are scarce. Here, we used bioinformatics tools to verify the effect of the main pathogenic variants reported in the gene: c.366-588del, c.589-2A>G, c.646A>T, c.570C>A, c.369-372delGCTC, c.202C>T, c.514G>A, and c.144C>A in the 1-AGPAT 2 membrane topology. We also correlated the phenotype of CGL1 subjects harboring these variants to understand the genotype-phenotype relationship. We provided an integrative view of clinical, genetic, and metabolic features from CGL1 individuals, helping to understand the role of 1-AGPAT 2 in the pathogenesis of this rare disease. Data reviewed here highlight the importance of new molecular studies to improve our knowledge concerning clinical and genetic heterogeneity in CGL1.
1-酰基甘油-3-磷酸O-酰基转移酶(1-AGPAT)是一个由11种同工型组成的酶家族。值得注意的是,1-AGPAT 2自发现以来是研究最多的同工型,是甘油三酯合成途径中的关键酶,可将溶血磷脂酸转化为磷脂酸。此外,基因表达对脂肪细胞的发育和成熟至关重要。1-AGPAT 2缺陷会导致与脂肪组织(AT)相关的重大病理生理改变。该基因的致病变异是1型先天性全身性脂肪营养不良(CGL1)的分子病因,患者从出生起就没有脂肪组织。在代谢方面,这些个体有多种代谢并发症,包括低瘦素血症、低脂联素血症、高血糖和高甘油三酯血症。此外,在CGL1患者中发现了许多极大影响1-AGPAT 2氨基酸序列、三级结构及其跨膜和功能域的致病变异。然而,研究该疾病基因型与表型关系的研究很少。在此,我们使用生物信息学工具来验证1-AGPAT 2基因中报道的主要致病变异:c.366-588del、c.589-2A>G、c.646A>T、c.570C>A、c.369-372delGCTC、c.202C>T、c.514G>A和c.144C>A对其膜拓扑结构的影响。我们还将携带这些变异的CGL1受试者的表型进行关联,以了解基因型与表型的关系。我们提供了CGL1个体临床、遗传和代谢特征的综合观点,有助于理解1-AGPAT 2在这种罕见疾病发病机制中的作用。此处综述的数据突出了新分子研究对于增进我们对CGL1临床和遗传异质性认识的重要性。